2ONE ⁣Labs Inc. Receives Favorable Review from FDA for Premarket ⁢Tobacco Product Application

2ONE ⁢Labs Inc. has announced that its Premarket Tobacco ⁢Product Application (PMTA) for its 2ONE brand ⁢nicotine pouches has received a favorable review from the US Food⁣ and⁤ Drug Administration (FDA).

Vincent‌ Schuman, CEO of‍ 2ONE Labs, expressed his enthusiasm for the favorable opinion received ⁣from the FDA, stating: “This means that the PMTA for 2ONE will move to‌ the next ‌important step in the FDA review. Our company will continue to fully fund ‌this application until it is ⁣successful, and⁣ our wholesale, retail and sponsor ⁤partners ‌should see this ‘favorable‌ review’ ⁣as a ​sign ⁤of our ability to navigate this complex ⁤process, and our unwavering commitment to ensure ⁢the long-term availability of‌ the 2ONE brand in the⁤ US‌ market.”

“We created 2ONE nicotine pouches for adult⁣ users (aged ‍21​ and over), who find it difficult to ⁣quit‍ heated tobacco products or traditional oral products based on leaves. ​The availability of the 2ONE brand on the market over the last five years, the interest generated by ⁤our brand as well as⁢ its ⁤development thanks to strong distribution partnerships, such‍ as with Circle K, have shown that it is possible, even for innovative companies, to​ identify and raise awareness of unique‌ brands that offer‌ the ‍perfect​ transition product for adult⁤ consumers. This⁤ favorable opinion from the FDA following⁤ submission‍ of the PMTA for 2ONE is very encouraging, and only strengthens our⁢ determination to continue ​to ⁢meet the​ needs of adult consumers who wish to quit smoking.”

2ONE Nicotine‌ Pouches ⁢are available in various nicotine levels and pleasant flavors at over⁤ 18,000 retail locations nationwide.